NovaBay Pharmaceuticals Inc NBY
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if NBY is a good fit for your portfolio.
News
-
NovaBay Pharmaceuticals Announces Pricing of $3.5 Million Underwritten Public Offering
-
NovaBay Pharmaceuticals Offers 20% Discounts on Avenova Eyecare Products During Amazon Prime Day
-
NovaBay Pharmaceuticals Reports Preliminary Second Quarter 2024 Net Revenue of $2.4 Million
-
NovaBay Pharmaceuticals and Eyenovia Commence Co-Promotion Activities
-
NovaBay Pharmaceuticals Supports National Dry Eye Awareness Month with Multiple Avenova Product Promotions
-
NovaBay Pharmaceuticals Plan of Compliance Accepted by the NYSE American
-
NovaBay Pharmaceuticals Announces Approval of All Proposals at its 2024 Annual Meeting of Stockholders and Provides Other Corporate Updates
-
NovaBay Pharmaceuticals Launches Avenova Product Bundles for Individualized Relief from Multifactorial Dry Eye Symptoms
Trading Information
- Previous Close Price
- $1.94
- Day Range
- $0.69–0.88
- 52-Week Range
- $0.69–44.80
- Bid/Ask
- $0.72 / $0.73
- Market Cap
- $944,206.40
- Volume/Avg
- 4.3 Mil / 379,976
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 0.01
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
NovaBay Pharmaceuticals Inc is a biopharmaceutical company that develops and sells scientifically-created and clinically eyecare and skincare products. Its product, Avenova Antimicrobial Lid and Lash Solution (Avenova Spray), is laboratory tested to have broad antimicrobial properties as it removes foreign material including microorganisms and debris from the skin around the eye, including the eyelid. Avenova Spray is available directly to consumers through online distribution channels and is also often prescribed and dispensed by eyecare professionals for blepharitis and dry-eye disease. It has two reportable segments: Eyecare and Wound Care and Skincare.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 26
- Website
- https://www.novabay.com
Valuation
Metric
|
NBY
|
---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | — |
Price/Sales | 0.01 |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
Metric
|
NBY
|
---|---|
Quick Ratio | 0.65 |
Current Ratio | 0.92 |
Interest Coverage | — |
Quick Ratio
NBY
Profitability
Metric
|
NBY
|
---|---|
Return on Assets (Normalized) | −67.39% |
Return on Equity (Normalized) | −224.23% |
Return on Invested Capital (Normalized) | −95.13% |
Return on Assets
NBY
Biotechnology Industry Comparables
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
---|---|---|---|---|---|---|
Novo Nordisk A/S ADR
NVO
| Fznppyhkkb | Pshb | $565.6 Bil | |||
Vertex Pharmaceuticals Inc
VRTX
| Fsbymggh | Xnctdk | $127.8 Bil | |||
Regeneron Pharmaceuticals Inc
REGN
| Hrjfqqgc | Wtxvg | $117.3 Bil | |||
Moderna Inc
MRNA
| Ljqjncmcw | Jqdt | $46.1 Bil | |||
Alnylam Pharmaceuticals Inc
ALNY
| Zgzbzptx | Sfnmjx | $29.7 Bil | |||
argenx SE ADR
ARGX
| Kwmcjxgx | Qrw | $28.8 Bil | |||
BioNTech SE ADR
BNTX
| Njnhzjgn | Bpyg | $20.7 Bil | |||
Biomarin Pharmaceutical Inc
BMRN
| Txqnhtdd | Zvpzmq | $16.1 Bil | |||
United Therapeutics Corp
UTHR
| Cbdkcrdnw | Tvb | $14.9 Bil | |||
Incyte Corp
INCY
| Xykybzfh | Wsythz | $13.5 Bil |